Evoke Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 433.4%.

Top 19 shareholders own 24.89% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.97%	Nantahala Capital Management, LLC	148,194	US$644.6k	163%	0.05%
4.82%	Laurence Lytton	71,610	US$311.5k	0%	no data
4.63%	Bleichroeder LP	68,750	US$299.1k	0%	0.07%
4.12%	Lytton-Kambara Foundation, Endowment Arm	61,274	US$266.5k	0%	37.69%
0.79%	Corsair Capital Management, L.P.	11,667	US$50.8k	0%	0.01%
0.16%	David Gonyer	2,360	US$10.3k	0%	no data
0.16%	Cam Garner	2,331	US$10.1k	0%	no data
0.11%	Matthew D'Onofrio	1,653	US$7.2k	0%	no data
0.055%	Tower Research Capital Europe Limited	816	US$3.5k	31%	no data
0.028%	Mark Kowieski	417	US$1.8k	0%	no data
0.024%	Marilyn Carlson	360	US$1.6k	0%	no data
0.009%	Malcolm Hill	134	US$583.1	0%	no data
0.0082%	BlackRock, Inc.	122	US$530.7	0.83%	no data
0.0061%	UBS Asset Management AG	90	US$391.7	-2.17%	no data
0.0021%	Morgan Stanley, Investment Banking and Brokerage Investments	31	US$135.1	0%	no data
0.0019%	Todd Brady	28	US$121.5	0%	no data
0.0017%	Bank of America Corporation, Asset Management Arm	25	US$108.6	400%	no data
0.0011%	NewEdge Advisors, LLC	17	US$73.7	0%	no data
0.00027%	Citigroup Inc.,Banking and Securities Investments	4	US$17.5	0%	no data